Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | PI4KA | P42356 | 4/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.51 |
| ▸ | GMPS | P49915 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | GAPDH | P04406 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799646 | 1.00 | SLC28A1 (0.56) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL444963 | 0.87 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL29362292 | 0.85 | SLC28A1 (0.57) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL6756465 | 0.85 | SLC28A1 (0.57) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL2335292 | 0.85 | SLC28A1 (0.57) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL9956204 | 0.85 | SLC28A1 (0.57) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL25222252 | 0.84 | SLC28A1 (0.54) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL29786250 | 0.84 | SLC28A1 (0.54) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL3466617 | 0.84 | SLC28A1 (0.56) | SLC28A1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL66047 | 0.84 | SLC28A1 (0.56) | SLC28A1ADORA3ADORA2API4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| CN-114076805-A | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-02-22 | — | — | CN | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3215617-B1 | SYSTEMS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE INC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4359527-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240110179-A1 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | EDITAS MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | EDITAS MEDICINE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | EDITAS MEDICINE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2010062404-A2 | N-FMOC NUCLEOSIDES AND PHOSPHORAMIDITES, AND OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010027512-A9 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010027512-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
| WO-2004058252-A2 | ANTI-CANCER AGENTS COMPRISING ALKB INHIBITORS AND ALKYLATING AGENTS | ISIS INNOVATION LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| EP-1042348-A4 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1042348-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031119-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | HLA-C, HLA-DRB1, HLA-B | SLC28A1 1852/4885ADORA3 3662/4885ADORA2A 2375/4885 |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | MCL1, BCL2L11, BCL2L13 | SLC28A1 2740/4885ADORA3 3683/4885ADORA2A 2447/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | SLC28A1 772/4885ADORA3 77/4885ADORA2A 82/4885 |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | DCLRE1B, MPG, UNG | SLC28A1 4259/4885ADORA3 3421/4885ADORA2A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.